AAO 2023: OcuTerra's CEO shares update on diabetic retinopathy treatment study
Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
AAO 2023: Weight loss drug does not appear to worsen diabetic eye disease in most patients
Researchers are addressing growing concern over vision loss in people taking semaglutideat the American Academy of Ophthalmology annual meeting in San Francisco.
AAO 2023: Shining the spotlight on advances in artificial intelligence
The latest innovations are in focus at the 127th annual meeting of the American Academy of Ophthalmology, being held at the Moscone Center in San Francisco.
FDA grants Toku Breakthrough Device status for its cardiovascular risk AI platform
The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.
Clearside Biomedical completes recruitment in ODYSSEY Phase 2b clinical trial of CLS-AX in wet AMD
The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.
Prevent Blindness offers informational resources to ophthalmologists, for diabetes-related Eye Disease Awareness Month
Prevent Blindness is offering videos, fact sheets, social media graphics and PowerPoint presentations to educate the public on the potential effects diabetes may have on vision.
AAO 2023: Museum of the Eye a can’t miss for ophthalmologists
The collection at the Truhlsen-Marmor Museum of the Eye includes more than 38,000 objects, including rare books, instruments and immersive educational materials.
Study: “Pseudo cell” formulation targets vitreoretinal disease
Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.
FDA approves faricimab-svoa for the treatment of retinal vein occlusion
According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.
Visgenx issued patent for compositions of ELOVL2 gene therapy
The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.
Bausch + Lomb rolls out new surgical planning software for Eyetelligence platform
According to the company, the software is designed to streamline the flow of information, surgical planning, and enable electronic medical record and diagnostic device integration.
Harrow completes transfer of NDAs and launches 5 products in the US
In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.
Study: Collaboration across disciplines ensuring fairness of AI in healthcare
According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.
Study: Molecular age of the eye determined for the first time
The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.
Conflict in Israel could have dire impact on ophthalmic care in country
In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.
Retina Society 2023: Subgroup analyses of phase 1 DAVIO Trial of EYP-1901 demonstrating reduced treatment burden in wet AMD
At the 56th annual Retina Society congress in New York, David Boyer, MD, gave a presentation titled, "Subgroup analyses of phase 1 DAVIO Trial of EYP-1901 demonstrating reduced treatment burden in wet age-related macular degeneration."
Retina Society 2023: A comparison of the antiangiogenic profile of tyrosine kinase inhibitors vorolanib, axitinib, and sunitinib
Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."
Study: Defective EMC1 protein may contribute to a severe ocular disorder, familial exudative vitreoretinopathy
Researchers note their work reports a novel candidate gene for FEVR, which expands the spectrum of EMC1 variants and EMC1-related phenotypes, providing evidence for the prenatal diagnosis of candidate disease-causing EMC1 variants in FEVR.
ICTER researchers achieve potential breakthrough in the diagnosis of eye diseases
Researchers at the Warsaw, Poland-based International Center for Translational Eye Research decided to change that by introducing a new imaging method derived from optical coherence tomography. This led to the creation of even more advanced spatio-temporal optical coherence tomography.
Faricimab maintained vision improvements with extended treatment intervals up to 4 months for people with retinal vein occlusion in phase III studies
According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.
Innovent doses first patient in Phase 3 STAR clinical trial for nAMD
According to the company, a change from base line best corrected visual acuity based on an average at week 44, 48 and 52 serves as the primary endpoint.
RG6501 phase 1/2a results show evidence of improvement of outer retinal structure in patients with GA
G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
Apellis provides update on cases of retinal vasculitis among patients treated with pegcetacoplan injection
The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.
EURETINA 2023: The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study
Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.
EURETINA 2023: Varun Chaudhary, MD, discusses posturing after macular hole surgery
Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."
NIH awards researchers $1.2M to develop robotic eye examination system
Researchers have developed a robotic system that automatically positions examination sensors to scan human eyes.
Eye health: What should patients know?
Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."
FDA grants 510(k) clearance to Altris IMS platform
Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and central retinal vein occlusion.
Questions in Ophthalmology: What do you wish patients knew about eye health?
An expert opinion: What do you wish patients knew about eye health?
2 Clarke Drive Cranbury, NJ 08512